AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

enVVeno Medical Corporati... (NVNO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.84

0.25 (6.96%)

At close: Feb 20, 2025, 3:59 PM

3.82

-0.53%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.61
Market Cap	67.34M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.29
PE Ratio (ttm)	-2.98
Forward PE	n/a
Analyst	n/a

Ask	4
Volume	132,818
Avg. Volume (20D)	140,659
Open	3.60
Previous Close	3.59
Day's Range	3.48 - 3.84
52-Week Range	2.45 - 6.97
Beta	undefined

About NVNO

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blo...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date May 31, 2018

Employees 31

Stock Exchange NASDAQ

Ticker Symbol NVNO

Website https://www.envveno.com

Full Company Profile

Why Price Moved

4 months ago

-28%

EnVVeno Medical shares are trading lower after the... Unlock content with Pro Subscription

4 months ago

-1.75%

EnVVeno Medical shares are trading lower after the company announced a proposed public offering.

News

2 days ago · accessnewswire.com

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of...

2 days ago · accessnewswire.com

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision ...

2 weeks ago · accessnewswire.com

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a cli...

2 months ago · zacks.com

NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain

The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.